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Abstract Reperfusion of ischemic myocardium results in
apoptotic cell death and DNA fragmentation. Several transcrip-
tion factors are known to regulate the apoptotic cell death. This
study sought to examine the regulation of cardiomyocyte
apoptosis by these transcription factors. Isolated working rat
hearts were divided into six groups: control, 15 min ischemia, 60
min ischemia, 15 min ischemia followed by 2 h reperfusion,
ischemic stress adaptation by subjecting the hearts to four cyclic
episodes to 5 min ischemia, each followed by 10 min of
reperfusion, and adaptation followed by 15 min ischemia and
2 h reperfusion. Redox-regulated transcription factors, NFUB and
AP-1 and the expression of two anti- and pro-apoptotic genes,
Bcl-2 and p53 were determined. The results demonstrated NFUB
and AP-1 progressively and steadily increased as a function of
the duration of ischemia. In the adapted heart, NFUB binding
remained high while AP-1 binding was lowered to almost baseline
value. The anti-oxidant gene, Bcl-2 was downregulated in the
ischemic/reperfused heart, but upregulated in the preconditioned
myocardium. Significant induction of the expression of p53
occurred after ischemia and reperfusion. Apoptotic cells were
barely detected in the adapted myocardium which was subjected
to the same ischemia/reperfusion protocol. The results demon-
strate for the first time differential regulation of cardiomyocyte
apoptosis by pro- and anti-apoptotic transcription factors and
genes as a function of different durations of ischemia and
reperfusion. ß 2000 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Programmed cell death or apoptosis is recognized as a
physiological counter part of cell replication, and is the con-
tributing cause of cardiomyocyte cell death during ischemia/
reperfusion, myocardial infarction, and heart failure [1,2]. It is
an energy requiring process; needs de novo pro apoptotic
gene expression (p53, bax etc.), and directed by an in born
genetic program. The terminal result of this program is the
fragmentation of nuclear DNA which is associated with ultra-
structural changes in cellular morphology, while the function-
al integrity of the cell membrane still remains intact [3]. How-
ever, the exact mechanisms by which apoptosis is initiated in
vivo still remains unclear. Our initial studies have demon-
strated increased apoptosis in concert with nuclear fragmen-
tation in the ischemic reperfused myocardium [4]. Myocardial
adaptation to ischemic stress by repeated ischemia and reper-
fusion inhibited apoptotic cell death and DNA laddering ap-
parently by reducing oxidative stress [5].
There are two well-known redox-regulated proteins, NFUB
and AP-1, which participate in the regulation of apoptosis in
some cell types [6]. The transcription factor NFUB, a nuclear
protein of the Rel oncogene family, is involved in the regu-
lation of numerous genes [7]. It exists in the cytoplasm as an
inactive form, and stabilized by an inhibitory subunit IUB,
which inhibits its DNA binding activity. The transcriptional
factors c-Jun and c-Fos form heterodimers or homodimers
which binds to DNA and the complex formed by this proteins
is AP-1 [8]. Recent studies have revealed that like AP-1,
NFkB also stimulates or inhibits oxidative stress induced ap-
optosis in a trigger-dependent or a cell type speci¢c manner
[9]. In various cell lines wild-type-P53 (transcription factor,
pro-apoptotic gene), induced by DNA damage has been
shown to induce programmed cell death or apoptosis. It is
reported that p53 protein functions as an active transcription
factor in lesioned brain [10]. How activation of p53 promotes
apoptosis is unclear, but it might involve Bax [11], a series of
p53-inducible genes [12] or signaling through Fas-related
pathways [13]. There are other p53 e¡ectors which include
caspases that execute apoptotic cell death [14]. Several studies
on the master controller gene of apoptosis, p53, reveal con-
£icting results [15]. The proteins bcl-2 (anti-apoptotic or anti-
death) and bax (pro-apoptotic) have important regulatory in-
£uences.
No study has been performed to show the behavior of these
redox-sensitive transcription factors during di¡erent durations
of ischemia and reperfusion. To explore molecular mecha-
nisms involved in apoptosis, redox sensitive transacting mol-
ecules, AP-1, NFUB as well as p53 and bcl-2 were determined
in the heart as a function of ischemic and reperfusion time. In
order to determine how these redox-regulated molecules gov-
ern apoptosis, cardiomyocyte apoptosis was also evaluated
during di¡erent periods of ischemia, reperfusion and ischemic
preconditioning.
2. Materials and methods
2.1. Chemicals
p65 antibody was obtained from Santa Cruz Biotechnological Co.,
CA, USA. Gel-Shift Assay kits for NFUB and AP-1 were purchased
from Promega, Madison, WI, USA. cDNA probe for bcl-2 was ob-
tained from Oncor, Gaithersburg, MD, USA. P53 anti-sense and
sense primers were purchased from Stratagene, La Jolla, CA, USA.
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DNA labelling kit was purchased from Boehringer Mannheim, Indi-
anapolis, IN, USA. [Q-32p]ATP and [K-32P]dCTP were obtained from
Amersham, Arlington Heights, IL, USA. All other chemicals were of
high purity and obtained from Sigma Chemical Co., St. Louis, MO,
USA.
2.2. Isolated perfused heart preparation
Isolated perfused heart preparation was performed [16]. The hearts
were divided into six groups, six in each group. After stabilization the
hearts were perfused with KHB bu¡er for 195 min (Group I), Group
II hearts were subjected to 15 min of global ischemia, Group III
hearts were subjected to 60 min of ischemia only, Group IV hearts
were perfused with KHB for l h and then subjected to 15 min of
global ischemia followed by 120 min of reperfusion. In Group V,
the hearts were subjected to ischemic preconditioning by repeated
ischemia and reperfusion. For this, global ischemia was induced for
5 min followed by 10 min of reperfusion, repeating the process four
times (4UPC) as described previously [17]. Group VI hearts were
subjected to 4UPC followed by 15 min ischemia and 120 min of
reperfusion. The ¢rst 10 min of reperfusion was in the retrograde
mode to allow for post-ischemic stabilization and thereafter in the
antegrade working mode to allow for assessment of functional param-
eters. For NFUB and AP-1 binding activity as well as for Bcl-2 and
p53 gene expression, left ventricles from the control and experimental
hearts were kept frozen at liquid nitrogen temperature. The extent of
myocardial apoptosis was also evaluated in the heart after each ex-
periment.
2.3. Electrophoretic mobility shift assay (EMSA) for NFUB and AP-1
Gel shift assay was performed according to the manufacturer’s
(Promega) protocol with slight modi¢cation. Nuclear proteins were
isolated from the heart and gel-shift assays for NFUB and AP-1
were performed [18].
2.4. Northern blot analysis of Bcl-2
Total RNA was extracted from the heart tissues by the acid-guani-
dinium thiocyanate-phenol-chloroform method as described previ-
ously [19]. The results of densitometric scanning were normalized rel-
ative to the signal obtained by using GAPDH cDNA.
2.5. RT-PCR for P53
The cDNA was synthesized by reverse transcription reaction (255
Wl) of 1 Wg of total RNA isolated from control, ischemic, ischemic/
reperfused and adapted rat myocardium. The resulting cDNAs were
ampli¢ed by PCR using 1.5 Wl of the RT reaction product in PCR
bu¡er containing 2.5 units Taq DNA polymerase (Boehringer Mann-
heim, Indianapolis, IN, USA), 200 mM dNTPs and 0.6 mM of sense
(5P-CCTGCCCTCAACAAGATGTTTTG-3P) and antisense (5P-TCA-
AAGCTGTTCCGTCCCAG-3P) primer of P53 and sense 5P-TGGA-
ATCCTGTGGCATCCATGAAAC-3P and antisense 5P-TAAAACG-
CAGCTCAGTAACAGTCCG-3P primers of L-Actin (as internal
control) for 25 cycles in a thermal cycler. When the sequence for
L-actin was used in the initial cycle, denaturation was extended to
4 min. Subsequent cycles were: denaturation 94‡C 30 s; annealing
58‡C 30 s; elongation 72‡C 30 s; and ¢nal extension 72‡C 10 min.
After ampli¢cation, 10 Wl of each PCR product, along with a ladder
of known molecular weights were electrophoresed in TBE bu¡er in a
2% agarose gel containing 1 mg/ml ethidium bromide, and photo-
graphed with a Kodak DC120 Digital Camera Dedicated system
which provided photographs and semiquantitative measures of the
£uorescent intensity of the bands. Quantitation of the data was
done by densitometric scanning using L-actin as a control.
2.6. Evaluation of apoptosis
Immunohistochemical detection of apoptotic cells was carried out
using TUNEL [20] assay method in conjunction with an antibody
against myosin heavy chain to speci¢cally identify apoptotic cardio-
myocytes.
2.7. Statistical analysis
For statistical analysis, a two-way analysis of variance (ANOVA)
followed by Sche¡e’s test was ¢rst carried out using Primer Computer
Program (McGraw-Hill, 1988) to test for any di¡erences between
groups. If di¡erences were established, the values were compared us-
ing Student’s t-test. The values were expressed as mean þ S.E.M. The
results were considered signi¢cant if P was less than 0.05.
3. Results
3.1. The NFUB binding activity during di¡erent duration of
ischemia, ischemia reperfusion and ischemic
preconditioning
NFUB binding activity was found to be very low in non-
ischemic control hearts (Fig. 1A). Global ischemia for 15 and
60 min signi¢cantly increased the translocation of NFUB from
the cytosol to the nucleus (Fig. 1B,C). NFUB binding activity
was also increased signi¢cantly (5-fold, Fig. 1F) for the is-
chemically preconditioned hearts when compared to the ische-
mic reperfused myocardium (Fig. 1D). To con¢rm the specif-
icity of NFUB binding activity, we performed supershift assays
with polyclonal antibody recognizing NFUB p65 subunit (as
shown in lanes 1G and 1H).
3.2. The consensus AP-1 binding activity during di¡erent
duration of ischemia, ischemia/reperfusion and ischemic
preconditioning
EMSA indicated increased AP-1 binding activity in the is-
chemic heart (15 min as well as 60 min) rat heart (Fig. 2, lane
B and lane C) compared the to control perfused Group (lane
A). Reperfusion of 15 min ischemic heart for 120 min also
demonstrated signi¢cantly higher AP1 binding activity com-
pared to the control. In the ischemically adapted groups
(4UPC), the binding activity of AP-1 was signi¢cantly af-
fected. The densitometry scanning by image analyzer showed
signi¢cant decrease in its binding activity in the ischemic pre-
conditioned group compared to the ischemic as well as the
ischemic/reperfused group (the value is similar to the control
group).
Fig. 1. E¡ect of di¡erent durations of ischemia, ischemia/reperfusion
and ischemic preconditioning on the DNA binding activity of
NFUB. Lane A = perfused control heart, lane B = 15 min ischemia,
lane C = 60 min ischemia, lane D = 15 min ischemia and 120 min re-
perfusion, lane E = PC, lane F = PC+120 min reperfusion, lanes G
and H = Band shift (super) by using P65 antibody. Results are rep-
resentative of at least six di¡erent experiments per group.
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3.3. The expression of p53 during ischemia, ischemia/
reperfusion and ischemic preconditioning
The level of of p53 mRNA was assessed by performing RT-
PCR on samples prepared from control perfused, 15 min and
60 min of ischemia, ischemic-reperfused, and ischemic precon-
ditioned rat myocardium. The results of densitometric scan-
ning (means þ S.E.M.) for six di¡erent experiments for each
time points are shown with the blot. Transcript of p53 was
barely detectable in the control perfused (Fig. 3A), ischemic
(Fig. 3B,C) and preconditioned (Fig. 3E,F) hearts. Maximal
induction was achieved in the ischemic-reperfused myocardi-
um (Fig. 3D). L-Actin RT-PCR products, analyzed as internal
control, were unchanged during the course of the experiments.
3.4. The expression of Bcl2 during ischemia, ischemia/
reperfusion and ischemic preconditioning
Northern blot analysis revealed Bcl-2 gene upregulation in
ischemically adapted hearts (4UPC, 4UPC+ischemia/reperfu-
sion, Fig. 4E,F) compared to the control hearts. To the con-
trary, prolonged reperfusion (2 h) after acute ischemia (15 min)
downregulated Bcl-2 gene signi¢cantly as shown in Fig. 4D.
Ischemia alone had no in£uence on Bcl-2 gene expression as
shown in Fig. 4B,C. The results of densitometric scanning
(means þ S.E.M.) for six di¡erent experiments for each time
point are now shown with the blot.
3.5. Evaluation of apoptotic cells during ischemia, ischemia/
reperfusion and preconditioning
We were unable to detect apoptotic cardiomyocytes in the
control and in the ischemic hearts which were not subjected to
reperfusion (Fig. 5A). Even 60 min of global ischemia could
not induce apoptosis, there was no sign of fragmented nuclear
DNA in these biopsies. Apoptotic cells were identi¢ed only in
the reperfused hearts. The extent of apoptosis increased with
the progression of reperfusion time. Apoptotic cardiomyo-
cytes were ¢rst evidenced after 90 min of reperfusion. The
number of apoptotic cells increased (24%) after 2 h reperfu-
sion as evidenced from the immunohistochemical staining of
Fig. 2. E¡ect di¡erent durations of ischemia, ischemia/reperfusion
and ischemic preconditioning on AP1 activity. Where lane A = per-
fused control heart, lane B = 15 min ischemia, lane C = 60 min ische-
mia, lane D = 15 min ischemia and 120 min reperfusion, lane
E = PC, lane F = PC+120 min reperfusion. Results are representative
of at least six di¡erent experiments per group.
Fig. 3. E¡ect of di¡erent durations of ischemia, ischemia/reperfusion
and ischemic preconditioning on the relative abundance of P53 tran-
scripts in heart tissue. Lane M = DNA molecular weight marker.
lane A = perfused control heart, lane B = 15 min ischemia, lane
C = 60 min ischemia, Lane D = 15 min ischemia and 120 min reper-
fusion, lane E = PC, lane F = PC+120 min reperfusion. *P6 0.05 as
compared to the baseline control.
Fig. 4. E¡ect of di¡erent durations of ischemia, ischemia/reperfusion
and ischemic preconditioning on the relative abundance of Bcl-2
mRNA in heart tissue by Northern blot. Analysis as described in
Section 2. The results of densitometric scanning (mean þ S.E.M.) for
six di¡erent experiments for each time point are shown by bar
graph. Where A = perfused control heart, B = 15 min ischemia,
C = 60 min ischemia, D = 15 min ischemia and 120 min reperfusion,
E = PC, F = PC+120 min reperfusion. *P6 0.05 as compared to the
baseline control.
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the extended DNA in these hearts (Fig. 5B). Ischemic precon-
ditioning reduced the number of apoptotic myocytes in the
reperfused myocardium signi¢cantly (to 5%).
4. Discussion
Recurrent episodes of myocardial ischemia are commonly
observed in patients with coronary artery disease who su¡er
from frequent angina pectoris or angioplasty of the left ante-
rior descending coronary artery. Reversibly injured myocardi-
um (by a short episode of ischemia followed by another short
period of reperfusion) renders the heart more resistant to a
longer ischemic-reperfusion period. Such adaptation is medi-
ated through the upregulation of the heart’s own cellular de-
fense via the accumulation of intracellular mediators and re-
programming of gene expression. Recent studies suggest that
the cytoprotection resulted from ischemic adaptation could be
applied to human heart and may constitute anti-ischemic ther-
apy to cure ischemic heart disease. Altered gene expression in
the cardiovascular tissues of diseased heart has been reported
[21]. Cardiomyocytes exposed to hypoxia revealed apoptotic
cell death as evidenced by DNA fragmentation in conjunction
with the expression of Fas mRNA [22]. Cardiomyocyte apo-
ptosis has been demonstrated after ischemia and reperfusion
[4], failing human heart [23] myocardial infarction [24] and in
senescent hearts [25]. The possible cause of the altered gene
regulation is the abnormal binding activities of some of the
transcription factors like NFUB and AP-1. Reactive oxygen
species are involved in signal transduction pathways leading
to the modulation of both AP-1 and NFUB which have been
implicated in the regulation of gene transcription. Recently, a
novel signal transduction pathway responsible for activating
NFUB has been described [26]. Cytoplasmic IUB complexes
are major targets in signal transduction pathways [27]. A nov-
el therapeutic strategy has been adopted to reduce the extent
of myocardial infarction, using in vivo transfer of a ‘decoy’ cis
element to bind the critical transcription factor NFUB and
thereby block the transactivation of cytokines and adhesion
molecule genes necessary for the myocardial reperfusion in-
jury [28].
In this report, we demonstrate for the ¢rst time the binding
activities of NFUB and AP-1 during di¡erent durations of
Fig. 5. Evaluation of cardiomyocyte apoptosis using antibody against myosin heavy chain in conjunction with Tunnel staining. Representative
photomicrographs showing apoptotic cardiomyocytes. Bar graphs showing average number of cardiomyocytes undergoing apoptosis. Results
are expressed as means þ S.E.M. of six di¡erent rats per group. *P6 0.05 compared to control, **P6 0.05 compared to the ischemic/reperfused
group. A = perfused control heart, B = 15 min ischemia, C = 60 min ischemia, D = 15 min ischemia and 120 min reperfusion, E = adapted,
F = adapted followed by 120 min reperfusion.
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ischemia, reperfusion and ischemic adaptation. Myocardial
adaptation to ischemia was achieved by four cyclic episodes
of 5 min of ischemia each followed by 10 min of reperfusion.
Such adaptation, was previously shown to exert powerful car-
dioprotective e¡ects for ischemic hearts [29]. The results of the
present study demonstrated that the binding activities of
NFUB and AP-1 progressively and steadily increased as a
function of the duration of ischemia. During subsequent re-
perfusion, NFUB binding activity goes down while AP-l activ-
ity continues to increase with reperfusion time. In adapted
myocardium, NFUB activity remains high while AP-1 binding
activity comes down to the baseline level. In the majority of
cells, NFUB exists as a cytoplasmic complex by binding with
its inhibitory protein IUBK. Phosphorylation of IUBK by oxi-
dative stress resulting from ischemia/reperfusion can cause
dissociation of IUB from NFUB. We have shown in Fig. 1,
an early activation of NFUB by ischemia in the myocardium
which may be a signaling mechanism for the induction of
immediate-early gene expression during subsequent stress
adaptation. The binding of NFUB remained high during sub-
sequent ischemia and reperfusion. Preconditioning of the
heart by repeated ischemia and reperfusion also resulted in
increased NFUB binding activities. When the preconditioned
myocardium was subjected to ischemia/reperfusion protocol,
signi¢cantly higher binding activity of NFUB prevailed while
AP-1 binding became downregulated. We have also investi-
gated the loss of IUBK protein after dissociation in the cyto-
plasm caused by ischemia/reperfusion and preconditioning.
The kinetics of NFUB binding activity in the nuclear extracts
correlated with the kinetics for IUBK protein disappearance in
the cytoplasm. The data (not shown) suggest that the disap-
pearance of IUBK protein from cytoplasm resulted in the
translocation of NFUB complex to the nucleus as an active
form.
The results of our study indicate a direct correlation of
cardiomyocyte apoptosis with AP-l and indirect or minimal
correlation with NFUB. For example, ischemia as well as re-
perfusion of ischemic myocardium resulted in the activation
of AP-l simultaneously causing apoptotic cell death (Figs. 2
and 5). Conversely, ischemic stress adaptation downregulated
AP-1 (close to baseline control) and attenuated apoptosis.
These results are consistent with previous observations that
increased expression of components of AP-1 is linked to ap-
optosis [30]. A recent study demonstrated that c-Jun/AP-1,
but not NFUB, is a mediator for oxidant-initiated apoptosis
in glomerular mesangial cells [31]. In this study, using North-
ern blot analysis and transient transfection assays with report-
er plasmids, the authors showed that H2O2 activated both
AP-1 and NFUB. Downregulation of c-Jun/AP-1 using a
transdominant negative mutant of c-Jun-inhibited apoptotic
cell death while use of a transdominant negative mutant of
p50 NFUB subunits did not a¡ect H2O2-mediated apoptosis.
NFUB on the other hand was activated during ischemia ische-
mia/reperfusion, but signi¢cantly activated during ischemic
stress adaptation. A previous study demonstrated that activa-
tion of NFUB is a necessary step for myocardial adaptation to
ischemic stress [5,32]. The results, thus, suggests that NFUB
may play a dual role as pro- and anti-apoptotic factor.
Recent analysis of the bcl-2 gene family reveals a complex
network regulating apoptosis. Within this bcl-2 gene family,
some of the candidates can suppress apoptosis while the
others can induce apoptosis [33]. Apoptosis initiated by vari-
ous di¡erent stimuli can be blocked by overexpressing bcl-2.
Therefore, investigation of the expression and regulation of
the bcl-2 family may provide some light on the mechanisms to
the susceptibility by ischemia-reperfusion-induced apoptosis
and reduction of apoptosis by stress adaptation. Furthermore,
apoptosis induced by c-Myc over expression has been found
to be p53-dependent and these cells can be rescued by bcl-2
gene expression [34]. One of the report suggests that growth
arrest and apoptosis are controlled by the p53 gene [35]. It is
already reported that the increased expression of wild-type
p53 can induce apoptosis in myeloid leukemia and colon can-
cers [36]. Both Apo-1/Fas and Bax have been reported to be
positively regulated by p53 on a transcriptional level [37].
Therefore, the regulation and expression of the p53 gene
may be of central importance to induction of apoptosis in
normal and tumor cells. These ¢ndings prompted us to inves-
tigate the regulation/status of these two genes p53 (pro-apo-
ptotic) and bcl-2 (anti-apoptotic) in ischemic, ischemic-reper-
fused and preconditioned heart. The level of p53 mRNA as
assessed by performing RT-PCR revealed important ¢ndings
in our system for the ¢rst time. Transcript of p53 was barely
detectable in control (perfused with bu¡er only) and 15 min as
well as 60 min ischemic rat myocardium as shown Fig. 3.
Whereas reperfusion of ischemic myocardium induced p53
signi¢cantly which established the role of p53 in ischemic
reperfused myocardium to induce apoptosis. Ischemic precon-
ditioning prevented p53 activation and inhibited apoptosis.
Bcl-2 had just an opposite trend of p53. The activation of
bcl-2 was associated with the inhibition of apoptosis (Figs. 4
and 5 ) in the preconditioned myocardium and downregula-
tion of this anti-death gene occurred in concert with the sig-
ni¢cant amount of apoptosis in the ischemic/reperfused myo-
cardium. We previously demonstrated that prolonged
reperfusion after ischemia caused downregulation of bcl-2 in
concert with enhanced DNA fragmentation [38]. The results
of the present study con¢rmed the previous ¢ndings and fur-
ther demonstrated di¡erential induction of the expression of
bcl-2 as a function of various durations of ischemia, reperfu-
sion and ischemic stress adaptation.
In summary, our results indicate that ischemia/reperfusion-
mediated cardiomyocyte apoptosis is regulated by several re-
dox-sensitive transcription factors and genes. Apoptosis oc-
curs in concert with an increase in AP-land p53 and decrease
in bcl-2. Consistent with this ¢nding, a reduction of AP-1 and
p53 and an increase in bcl-2 inhibits apoptosis. NFUB appears
to function both as a pro- and an anti-apoptotic transcription
factor.
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